Ketamine Panpharma (Ketamine Hydrochloride)

Ketamine Hydrochloride works by non‑competitive antagonism of the NMDA receptor, which reduces excitatory neurotransmission in the central nervous system. This action leads to dissociative anesthesia, while additional interactions with opioid receptors and catecholamine pathways contribute to its analgesic and sympathomimetic effects.

The dose of Ketamine Panpharma is determined by the prescribing clinician based on the patient’s age, weight, clinical condition, and the intended use (anesthesia, analgesia, or sedation). Specific dosing regimens are not disclosed here and should follow local medical guidelines and professional judgment.

The safety of Ketamine in pregnancy and lactation has not been definitively established. It is classified as a category unknown, and use should be limited to situations where the potential benefits outweigh the possible risks to the fetus or infant. Clinicians should exercise caution and discuss alternatives when possible.

To order Ketamine Panpharma, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any temperature‑controlled requirements), and necessary import documentation.

Compared with agents such as propofol or thiopental, ketamine provides dissociative anesthesia while preserving airway reflexes and offering cardiovascular stimulation rather than depression. This makes it useful in trauma or emergency settings where hemodynamic stability is crucial, though it may produce more vivid emergence phenomena than other agents.

Ketamine Panpharma should be stored below 25 °C in its original packaging, protected from moisture and light. The product should be kept in a secure, temperature‑controlled environment until use, and handling should follow standard aseptic techniques for injectable medicines.

Ketamine Panpharma is supplied as a sterile injectable solution for intramuscular (IM) or intravenous (IV) administration. The route and rate of injection are selected by the treating clinician based on the clinical scenario, with IV delivery providing rapid onset and IM offering a slightly slower, yet reliable, effect.

The most serious risks include respiratory depression, severe hypertension, cardiac arrhythmias, and emergence phenomena such as agitation or psychotic reactions. Rarely, anaphylactic reactions may occur. Continuous monitoring of cardiovascular and respiratory parameters is essential during and after administration.

Ketamine should be avoided in patients with known hypersensitivity to ketamine or its excipients, uncontrolled hypertension, severe coronary artery disease, or a history of psychosis or severe mental illness where emergence phenomena could be hazardous. Caution is also advised in patients with elevated intracranial pressure or those taking MAO inhibitors.